Peptide Complex Modulates Macrophage Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory drugs, both steroidal and non-steroidal, pose safety concerns due to their adverse effects on the gastrointestinal, cardiovascular, neurological, and renal systems, limiting their long-term use for managing inflammatory diseases.
Innovation Solution
A peptide complex comprising Abeta 1-42 peptide and undercarboxylated osteocalcin (Glu-OC) is developed to modulate inflammation by forming a complex that can be administered therapeutically, targeting macrophages to regulate inflammation without the severe side effects associated with existing drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroidal and non-steroidal anti-inflammatory drugs are used for managing inflammatory diseases, then the quality of life is improved and disease progression is managed, but severe gastrointestinal, cardiovascular, neurological and renal problems occur
Solution Approach 1:
The patent uses peptide complexes as intermediary substances that mediate between the immune system and inflammatory responses. These peptide complexes specifically target and modulate macrophage activation states, acting as a bridge to achieve anti-inflammatory effects without the broad-spectrum toxicity of conventional drugs. The peptide complexes serve as selective mediators that interact with specific immune cell receptors to produce targeted therapeutic effects.
Solution Approach 2:
The invention changes the chemical and structural parameters of anti-inflammatory agents by using peptide-based molecules instead of traditional steroidal or non-steroidal compounds. The peptide complexes have distinct molecular characteristics including specific amino acid sequences, three-dimensional structures, and biological properties that differ fundamentally from conventional drugs, enabling them to achieve therapeutic effects through different mechanisms with improved safety profiles.
2Duration of action of stationary object
If conventional anti-inflammatory drugs are administered for long term treatment, then disease management is achieved, but safety and tolerability concerns arise
Solution Approach 1:
The patent employs peptide complexes that are designed to be transient and biodegradable rather than persistent. These peptide-based therapeutics naturally degrade into amino acids through proteolytic enzymes in the body, creating short-lived therapeutic agents that provide temporary anti-inflammatory action without long-term accumulation or chronic toxicity. This disposability characteristic allows for repeated administration cycles with reduced safety concerns.
Data Source
AI summary
The present invention relates to compositions that are effective in management of inflammatory diseases. The disclosure provides a peptide complex comprising Abeta 1-42 and undercarboxylated osteocalcin which displays anti-inflammatory and immunomodulatory functions. The disclosure further provides with processes for preparing the compositions.